MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2022 International Congress

September 15-18, 2022. Madrid, Spain.

View by Title View Categories
Jump to:  View All • a b c d [e] f g h i j k l m n o p q r s t u v w x y z
  • Early experience using real-world monitoring to inform Parkinson’s management

    W. Chen, L. Kirkby, T. Jansen, G. Philips, T. Haynes, S. Little, J. Jiminez-Shahad, H. Zahed, P. Lin, R. Gilron (San Francisco, USA)

  • Early intervention with deep brain stimulation for children with ε-sarcoglycan myoclonus dystonia

    A. Salazar, M. Correa-Vela, M. González, L. Ispierto, J. Ferrero-Turrion, G. Español, A. Bescós, M. Tardáguila, B. Pérez-Dueñas (Barcelona, Spain)

  • Early Morning Dystonia in Parkinson’s Patients Receiving Opicapone versus Entacapone: a Post-Hoc Analysis of BIPARK-I

    F. Stocchi, J. Ferreira, W. Poewe, O. Rascol, A. Antonini, J-F. Rocha (Rome, Italy)

  • Early Synucleinopathy is Associated with Differential Regulation of Neurotransmission and Immune Related Genes

    J. Patterson, J. Kochmanski, A. Stoll, M. Kubik, C. Kemp, J. Howe, M. Duffy, K. Miller, A. Cole-Strauss, J. Beck, S. Counts, K. Steece-Collier, A. Bernstein, K. Luk, C. Sortwell (Grand Rapids, USA)

  • Edentulous stereotypy: Common lacunae in the identification of an old malady

    D. Desai, S. Desai (Anand, India)

  • EEG power-spectra parametrization and cognitive ability in Parkinson’s disease

    R. Shoorangiz, N. Slater, G. Hall-Mcmaster, E. Peterson, L. Livingston, S. Grenfell, K. Clifford, A. Harris, I. Kirk, L. Tippett, R. Jones, T. Anderson, T. Melzer, J. Dalrymple-Alford (Christchurch, New Zealand)

  • EEG-based Mapping of Resting-state Functional Brain Networks in Patients with Parkinson’s Disease

    L. Maidan, D. Possti, S. Leviashvili, Y. Ezra, D. Amgad, D. Ken, S. Groppa, M. Muthuraman (Tel aviv, Israel)

  • Effect of Aspartame on Parkinson’s Disease Progression and Severity

    D. Kushigian, O. Vaou (Boston, USA)

  • Effect of CDNF in a novel combination stressor model of Parkinson’s disease

    A. Singh, A. Panhelainen, M. Voutilainen (Helsinki, Finland)

  • Effect of clinical levodopa medication cycle on subthalamic beta band power during therapeutic deep brain stimulation in Parkinson’s disease

    L. Hammer, C. Oehrn, S. Cernera, A. Hahn, M. Shcherbakova, C. Smyth, S. Little, P. Starr (San Francisco, USA)

  • Effect of exercise on brain metabolism and energetics in PD

    C. Bevington, R. Jayde Williams, B. Pike, J. Mckenzie, J. Zhang, W. Luh, AJ. Stoessl, V. Sossi (Vancouver, Canada)

  • Effect of exercise on motor symptoms, non-motor symptoms and dopamine transporter imaging in Parkinson Disease

    J. Morley, J. Dubroff, G. Cheng, B. Taylor, S. Wood, J. Duda (Philadelphia, USA)

  • Effect of freezing of gait and antiparkinsonian medication on joint kinematics and kinetics in gait in patients with Parkinson’s disease

    T. Shida, D. Campos, C. Oliveira, R. Treza, S. Hondo, E. Los Angeles, C. Bernardo, L. Oliveira, M. Carvalho, D. Coelho (São Bernardo Campo, Brazil)

  • Effect of freezing of gait on the neural activity during the cognitive-motor conflict in step initiation in individuals with Parkinson’s disease: a case study

    L. de Oliveira, C. de Oliveira, P. Bazán, C. Bernardo, E. Los Angeles, M. Carvalho, J. Sato, A. de Lima-Pardini, D. Coelhodaniel, A. Baptista (Diadema, Brazil)

  • Effect of KW-6356, a novel adenosine A2A receptor antagonist/inverse agonist, on motor and non-motor symptoms in Parkinson’s disease patients as an adjunct to levodopa therapy: Results of Phase 2b study

    T. Maeda, K. Sugiyama, K. Yamada, M. Nishi, N. Hattori (Iwate, Japan)

  • Effect of levodopa-carbidopa intestinal gel on lower urinary tract symptoms in Parkinson’s disease: an Urodynamic study

    D. Rinaldi, O. Voglino, A. Tubaro, FE. Pontieri (rome, Italy)

  • Effect of lower limb vs. abdominal compression on mobility in orthostatic hypotension – a single-blinded, randomized, controlled, cross-over study in Parkinson’s disease

    S. Paschen, C. Hansen, J. Welzel, J. Albrecht, A. Atresaei, K. Aminian, KE. Zeuner, R. Romijnders, E. Warmerdam, PP. Urban, D. Berg, W. Maetzler (Kiel, Germany)

  • Effect of perception of vertical position on forward flexion posture in patients with Parkinson’s disease: A multicenter, observational study (interim report)

    M. Shiraishi, K. Mikami, H. Kamo, T. Kamo, T. Tsunemi, Y. Okuma, K. Fujimoto, Y. Yokota, S. Nogawa, T. Osada, M. Seki, H. Nagayama, T. Hatano, H. Nakajima, K. Suzuki, T. Yamamoto, Y. Yamano, N. Hattori, M. Ijima (Kawasaki, Japan)

  • Effect of rehabilitation interventions on freezing of gait in people with Parkinson’s disease: a systematic review and meta-analyses

    L. Goh, C. Canning, J. Song, L. Clemson, N. Allen (Camperdown, Australia)

  • Effect of Subthalamic Nucleus Stimulation (STN-DBS) on psychosocial function using the scale “SCOPA-PS” in patients with Parkinson’s Disease at the National Institute of Neurology and Neurosurgery in Mexico during 2007 to 2020.

    D. Sandoval-Lopez, K. Velázquez-Leonel, C. Alcalá-Romero, S. Santillán-Herrera, F. Juárez-Tovar, J. Villarreal-Serrano (Mexico City, Mexico)

  • Effect of the mGlu2/3 orthosteric agonist LY-404,039 on dyskinesia, psychosis-like behaviours, and parkinsonism in the MPTP-lesioned marmoset

    W. Kang, S. Nuara, J. Gourdon, P. Huot (Montreal, Canada)

  • Effect of wearing knee braces on unsteadiness on standing in a case with primary orthostatic tremor

    J. Tashiro, H. Ohtsuka, H. Fukaura, M. Hirotani, Y. Iida, T. Takahashi, S. Hamada, M. Nonaka, S. Honma, A. Takei, F. Moriwaka, K. Tashiro (Sapporo, Japan)

  • Effectiveness of a home-based exercise program on gait characteristics in an individual with Parkinson’s disease over a one-year period: A case study

    F. Khobkhun, P. Srivanitchapoom, J. Richards (Nakhon Pathom, Thailand)

  • Effectiveness of Combined tDCS and tNIRS on Motor Performance in Parkinson’s Disease – A Single Case Study

    N. Choudhary (Jodhpur, India)

  • Effects of a novel neurotrophic compound in an animal model of Parkinson’s disease

    T. Viljakainen, M. Voutilainen (Helsinki, Finland)

  • Effects of directional subthalamic deep brain stimulation on gait and balance in Parkinson Disease patients.

    S. Cherif, C. Olivier, J. Bourilhon, D. Bannier, D. Maltête, B. Lau, S. Derrey, E. Bardinet, C. Karachi, M. Welter (Paris, France)

  • EFFECTS OF DOPAMINERGIC MEDICATION ON REACTIVE AND PROACTIVE INHIBITORY CONTROL

    G. Mirabella, C. Mancini, O. Olivola, A. Rizzardi, V. Di Caprio, E. Ferrari, N. Modugno, A. Pilotto, A. Padovani (Brescia, Italy)

  • Effects of gait symmetry manipulation on cortico-subthalamic interhemispheric coupling in parkinsonian patients by use of virtual reality

    J. Reuss, A. Gulberti, M. Knorr, M. Sengelmann, T. Schneider, M. Schaper, W. Hamel, A. Engel, C. Gerloff, C. Moll, M. Pötter-Nerger (Hamburg, Germany)

  • Effects of Once-Daily Opicapone 50 mg on COMT activity: A Pooled Post-hoc Analysis of Two Phase 1 Studies

    G. Loewen, A. Vijan, K. Olson, T. O'Reilly, G. Liang, O. Klepitskaya (San Dieg, USA)

  • EFFECTS OF OPICAPONE IN PARKINSON DISEASE AS ASSESSED BY KINEMATIC TECHNIQUES

    D. Colella, A. de Biase, A. Cannavacciuolo, L. Angelini, A. Guerra, G. Paparella, A. Berardelli, G. Fabbrini, M. Bologna (Rome, Italy)

  • Effects of Parkinson’s disease and freezing of gait on the kinematic and kinetic gait parameters

    D. Campos, T. Shida, C. Oliveira, R. Treza, S. Hondo, E. Los Angeles, C. Bernardo, L. Oliveira, M. Carvalho, D. Coelho (São Bernardo Campos, Brazil)

  • Effects of Subthalamic Nucleus Deep Brain Stimulation on pain in Parkinson disease: Real-life observational prospective study

    I. Carvalho, D. Damas, I. Cunha, S. Caldeira, P. Monteiro, R. Pereira, F. Moreira (Coimbra, Portugal)

  • Effects of venlafaxine on neuropsychiatric and motor symptoms in patients with progressive supranuclear palsy

    M. Zeitzschel, M. Maheu, T. Donner, C. Gerloff, A. Gulberti, M. Pötter-Nerger (Hamburg, Germany)

  • Effects of Virtual Reality Immersion Level on Exercise Intensity and Motivation for Persons with Parkinson Disease

    J. Palmieri, R. Gallagher, J. Donoghue, N. Volino, H. Damodaran, J. Deutsch (Newark, USA)

  • Efficacy And Safety Of Unilateral MRgFUS Thalamotomy In Patients With Essential Tremor

    V. Sharma, K. Lyons, L. O'Brien, K. Au, J. Cheng, M. Kinsman, R. Pahwa (Kansas City, USA)

  • Efficacy of Apomorphine Sublingual Film Versus Subcutaneous Apomorphine for the Treatment of OFF Episodes in Parkinson’s Disease

    F. Stocchi, O. Rascol, W. Poewe, R. Chaudhuri, J. Kassubek, L. Lopez Manzanares, V. Leta, I. Zhang, A. Bowling, S. Wu, E. Pappert (Rome, Italy)

  • Efficacy of levodopa/benserazide dispersible tablet on delayed ON in Parkinson’s disease patients with motor fluctuations: a multicenter randomized open-label cross-over trial

    HJ. Chang, J. Park, S. Oh, CW. Shin, JW. Cho, JY. Lee (Seoul, Republic of Korea)

  • Efficacy of Magnetic resonance-guided focused ultrasound thalamotomy (MRgFUS thalamotomy) for refractory essential tremor (ET)-single center experience.

    T. Fay-Karmon, U. Kozlov, S. Anis, R. Shpigelman, S. Israeli-Korn, S. Hassin-Baer, Z. Zivli (Ramat Gan, Israel)

  • Electrical stimulation of muscle afferents for tremor reduction in essential tremor patients

    M. González Sánchez, JR. Pérez Sánchez, A. Pascual Valdunciel, F. Oliveira Barroso, S. Muceli, B. Adán-Barrientos, V. Escobar-Segura, M. Ki Jung, A. Muñoz González, A. Schneider, KP. Hoffmann, D. Farina, JL. Pons, FJ. Grandas Pérez (Madrid, Spain)

  • Electrophysiologic and Kinematic characterization of degenerative cerebellar ataxia

    J. Ganguly, O. Samotus, Y. Tamilselvam, Y. Mahdi, M. Tuesta, D. Aur, M. Jog (London, Canada)

  • Electrophysiological analysis of tremor in patients with writer’s cramp

    D. Biswas, R. Anandapadmanabhan, A. Vishnoi, R. Rajan, A. Srivastava (New Delhi, India)

  • Electrophysiological characteristics of tremor in patients with tick borne encephalitis

    M. Klarendic, N. Prezelj, K. Vogelnik, M. Kojovic (Ljubljana, Slovenia)

  • Electrophysiological correlates of neurological deficits in toxic-metabolic encephalopathy

    N. Prezelj, K. Vogelnik, B. štabuc, M. Kojovic (Ljubljana, Slovenia)

  • Electrophysiology and clinical description of Tremor in Spinocerebellar Ataxia 12 (SCA12)

    A. Srivastava, M. Narang, R. Rajan, M. Faruq (New Delhi, India)

  • Electrophysiology marker of levodopa induced dyskinesia in Parkinson disease

    H. Hawong, K. Chung, N. Swann (PORTLAND, USA)

  • Elimination of STN stimulation-induced dyskinesias with ViM DBS

    D. Shah-Zamora, J. Karl, L. Verhagen (Chicago, USA)

  • Embodied language in Parkinson disease: the case of demonstrative

    C. Giacobbe, Y. Coello, G. Santangelo (Caserta, Italy)

  • Emotion Recognition and Risk-Taking Behaviour in Early Parkinson’s Disease

    A. Slomp, D. de Waard, S. Vander Zee, S. Slingerland, J. Boertien, J. Spikman, T. van Laar, R. Huitema (Groningen, Netherlands)

  • Emotion Recognition in Multiple System Atrophy – an Eye-Tracking Study

    V. Sidoroff, F. Carbone, P. Ellmerer, S. Bair, A. Hoffmann, T. Maran, C. Raccagni, K. Seppi, G. Wenning, A. Djamshidian-Tehrani (6020, Austria)

  • Emotional arousal in patients with functional movement disorders: a pupillometry study

    M. Slovák, J. Anýž, J. Erlebach, Z. Forejtová, V. Fabián, T. Rošíková, L. Nováková, E. Růžička, MJ. Edwards, T. Serranová (Prague 2, Czech Republic)

  • Enabling Multi-domain Exercise Training in Parkinson’s Disease Through Wearable and Digital Health Technology

    B. Hu, T. Chomiak (Calgary, Canada)

  • Endocannabinoid Dysfunction in Human Disease: Neuro-Ocular DAGLA-related Syndrome (NODrS), a unique pediatric condition

    J. Friedman, A. Mazumder, D. Ogasawara, R. Abou Jamra, G. Bernard, E. Bertini, L. Burglen, A. Crawford, H. Cope, A. Derksen, L. Dure, E. Gantz, M. Koch-Hogrebe, A. Hurst, S. Mahida, P. Marshall, A. Micalizzi, A. Novelli, H. Peng, *. Rady-Children'S-Institute-For-Genomic-Medicine, D. Rodriguez, S. Robbins, L. Rutledge, R. Scalise, S. Schließke, V. Shashi, S. Srivastava, I. Thiffault, S. Topol, *. Undiagnosed-Disease-Network, L. Qebibo, D. Wieczorek, B. Cravatt, S. Haricharan, A. Torkamani, M. Bainbridge (San Diego, USA)

  • Environmental exposures and clinical phenotype in a sample of patients with Parkinson’s disease in the southwestern Colombian region: preliminary results

    J. Orozco Velez, H. Clavijo-Moran, D. álvarez-García, I. F Mata, B. Muñoz-Ospina (Cali, Colombia)

  • Environmental factors and Parkinson’s disease

    Y. Babajani, M. Salari, M. Afroozian, M. Etemadifar (Tehran, Islamic Republic of Iran)

  • Epidemiologic And Clinical Features Of Psychiatric Disorders In Patients With Parkinson’s Disease – A Retrospective Cohort Study

    O. Koniashvili, G. Khachiashvili, L. Gabunia (Tbilisi, Georgia)

  • Epidemiological, clinical and paraclinical characteristics of metals accumulation in brain in childhood

    A. Atrous, H. Ben Rhouma, Z. Miladi, T. Ben Younes, H. Klaa, I. Kraoua, I. Benyoussef Turki (Ariana, Tunisia)

  • EPIDEMIOLOGY OF FUNCTIONAL MOVEMENT DISORDERS

    B. Yardimci Kara, N. Oksuz Gurlen, O. Dogu (Mersin, Turkey)

  • Epileptic seizures in patients with parkinsonism: experience of a tertiary centre

    C. Azoia, R. Jesus, A. Costa, A. Velon, P. Guimarães (Vila Real, Portugal)

  • ER Visits and Hospitalizations Among Patients Treated with Pimavanserin or Other-AAPs for Parkinson’s Disease Psychosis: Analysis of Medicare beneficiaries

    S. Kumar, N. Rashid, D. Doshi, K. Rajagopalan (Dover, USA)

  • Establishing and validating 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced zebrafish model of Parkinson’s disease

    W. Mohamed (Kuantan, Malaysia)

  • Estimating the Meaningful Within-Patient Change Threshold for the MDS-UPDRS Part III

    S. Zanigni, D. Trundell, A. Monnet, N. Shariati, E. Moore, E. Davies, N. Pross, G. Pagano, T. Nikolcheva (Basel, Switzerland)

  • Evaluation of Actigraphy-Based Circadian Rhythm and Motor Function Measures for Monitoring Treatment of Lewy Body Dementia in PRESENCE Study

    X. Dang, J. Wang, C. Battioui, M. Williamson, J. Zou, A. Hake, H. Zhang, B. Winger, J. Yang, K. Biglan (Cambridge, USA)

  • Evaluation of an Oral Health Questionnaire in Parkinson’s Disease to Facilitate a Multi-disciplinary Approach to improving Care Through Education

    J. Price, H. Martin, L. Ebenezer (Bronllys, Powys, United Kingdom)

  • Evaluation of Atrophy after Botulinum Toxin injection for Cervical Dystonia by MRI

    M. Salari, M. Etemadifar, S. Parvizi (Tehran, Islamic Republic of Iran)

  • Evaluation of Genetic influence of APOE on Clinical and motor functions among Idiopathic Parkinson’s Disease Patients; A comparative study

    W. Ibrahim, H. Shehata, L. Rashed, A. Sabbah, H. Amer (Cairo, Egypt)

  • Evaluation of hyperintense globus pallidus rim sign in seven-tesla MRI as a diagnostic biomarker in Wilson’s disease

    D. Su, Z. Zhang, Z. Zhang, T. Wu, J. Jing, T. Feng (Beijing, China)

  • Evaluation of ocular perfusion in Parkinson’s disease and association with clinical manifestations.

    A. Camacho-Ordonez, M. Rodriguez-Violante, A. Cervantes-Arriaga, A. Hernández-Medrano, O. Guerrero-Berger (Mexico, Mexico)

  • Evaluation of rapid eye movement behavioral disorder (RBD) in sporadic adult onset ataxia (SAOA)- A prospective observational study

    ANI. Das, A. Srivastava, A. Jaryal, R. Rajan (Delhi, India)

  • Evaluation of the anxiolytic effects of naringenin in rotenone-induced rat model of Parkinson’s disease by an elevated plus maze test

    S. Madiha (Karachi, Pakistan)

  • Evaluation of the association between total electrical energy delivered (TEED) and cognitive function six months after DBS in patients with Parkinson’s disease

    F. Ruggiero, F. Mameli, M. Dini, S. Marceglia, M. Prenassi, L. Borellini, F. Cogiamanian, E. Pirola, E. Zirone, D. Mellace, B. Capetti, L. Remore, G. Fiore, MR. Reitano, N. Maiorana, M. Locatelli, S. Barbieri, A. Priori, R. Ferrucci (Milan, Italy)

  • Evaluation of the effect of adding a mGlu2/3 orthosteric antagonist to a highly selective 5-HT2A antagonist on dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset

    S. Nuara, J. Gourdon, P. Huot (Montreal, Canada)

  • Evaluation of α-synuclein pathology and function in dopaminergic neurons derived from LRRK2 I1371V PD patient iPSCs

    I. Datta, S. Jagtap, C. Potdar (Bangalore, India)

  • Evoked resonant neural activity within the dorsolateral subthalamic nucleus as a biomarker for the targeting of deep brain stimulation for Parkinson’s disease

    H. Simpson, S. Xu, W. Lee, A. Begg, K. Bulluss, H. Mcdermott, W. Thevathasan, T. Perera (Melbourne, Australia)

  • Evolution of biochemical and clinical signature of GBA-related Parkinson’s Disease: a 2-year longitudinal study

    M. Avenali, S. Cerri, G. Ongari, C. Pacchetti, C. Tassorelli, EM. Valente, F. Blandini (Pavia, Italy)

  • Examining adaptive control in patients with Parkinson’s disease

    J. Kricheldorff, J. Ficke, K. Witt (Oldenburg, Germany)

  • Examining the sex differences in the prevalence and incidence of Parkinson disease

    A. Zirra, S. Rao, J. Bestwick, R. Rajalingam, C. Marras, C. Blauwendraat, I. Mata, A. Noyce (London, United Kingdom)

  • Excessive tearing; a paradoxical ocular manifestation of Parkinson’s disease

    S. Yaisawang, J. Sringean, N. Kasetsuwan, K. Pongpirol, R. Bhidayasiri (Bangkok, Thailand)

  • Execution of scientific tractography for presurgical preparation of area seizing abrasions: A study through the acquisition plus post-processing techniques contrasted to investigational revisions

    V. Rama Raju, G. Ramaraju, V. Ramaraju (Hyderabad, India)

  • Exenatide protects iPSC-derived dopaminergic neurons with A53T mutation through restoration of insulin signaling

    D. Athauda, J. Evans, A. Wernick, G. Virdi, M. Choi, K. D'Sa, Z. Shadman, N. Greig, T. Foltynie, S. Gandhi (London, United Kingdom)

  • Exosomes from human dental pulp stem cells as a cell-free drug delivery vehicle in vitro and in vivo chronic PD rat model through the intranasal route targeting efficacy & bio-distribution.

    I. Datta, A. Kaushal, K. Mondal (Bangalore, India)

  • Expanding the armamentarium of clinical use of apomorphine in movement disorders.

    S. Bansal, JR. Chai, M. Jog (London, Canada)

  • Expanding the services of Neurogenetic Clinic – Lessons learnt from Cerebellar Ataxia cohort

    P. Ponger, D. Barel, A. Mory, A. Kurolap, A. Bar David, H. Feldman Baris, N. Giladi, T. Gurevich (Tel Aviv, Israel)

  • Expectations of DBS: the patient’s perspective

    E. Sanesteban Beceiro, V. Gómez Mayordomo, A. Fernández Revuelta, C. Fernández García, R. García-Ramos, E. López Valdés, F. Alonso Frech (Madrid, Spain)

  • Experience with apomorphine infusion cartridge in France – evaluation of patient and healthcare team benefits

    M. Vérin, M. Demais (Rennes, France)

  • Explorative study of analysis of the role of NFL and IGF1 in Indian patients with PSP and its clinical correlation.

    R. Yelamanchi, S. Dey, R. Yadav, P. Pal, M. Debnath, V. Holla, N. Kamble, S. T N, T. Mullapudi (Bangalore, India)

  • Exploratory analysis of the effect of delayed-start prasinezumab on motor sign progression measured with the Roche PD Mobile Application v2: PASADENA Phase II Parts 1 and 2

    K. Taylor, F. Lipsmeier, E. Volkova-Volkmar, M. Scelsi, L. Essioux, A. Monnet, B. van Lier, H. Svoboda, T. Kustermann, W. Zago, T. Nikolcheva, R. Postuma, G. Pagano, M. Lindemann (Basel, Switzerland)

  • Exploratory delayed-start analysis of PASADENA evaluating the efficacy of prasinezumab on motor progression and motor complications in early-stage Parkinson’s disease

    G. Pagano, S. Zanigni, A. Monnet, K. Taylor, A. Hahn, T. Simuni, K. Marek, R. Postuma, N. Pavese, F. Stocchi, H. Svoboda, P. Fontoura, R. Doody, G. Kerchner, A. Bonni, T. Nikolcheva (Basel, Switzerland)

  • Exploring Driving Behaviour in Patients with Functional Neurological Disorders (FND)

    TJ. Lagrand (Brisbane, Australia)

  • Exploring the diversity of alleviating manoeuvres in Cervical Dystonia

    L. Avanzino, F. Di Biasio, G. Bonassi, E. Pelosin, N. Cothros, R. Marchese, D. Martino (Genoa, Italy)

  • Exploring the impact of central cholinergic dysfunction on cognitive functioning in patients of Parkinson’s disease with and without REM sleep behavior disorder

    A. Bhattacharya, K. Udupa, N. Kamble, M. Gothwal, S. Hegde, R. Yadav, PK. Pal (Bengaluru, India)

  • Exploring the morning akinesia in Parkinson’s disease with the wearable sensor STAT-ON

    N. Caballol, C. Pérez-López, A. Pérez-Soriano, A. Planas-Ballvé, A. ávila, P. Quispe, A. Bayés (Sant Joan Despí, Spain)

  • Exploring Young people’s role in providing relief to grandparents affected with Alzheimer

    M. Busgopaul (Port Louis, Mauritius)

  • Expression perception and timing in people with Parkinson’s Disease

    M. Gracey, C. Press, J. Cook (Birmingham, United Kingdom)

  • Eye closure during tasks in blepharospasm (BSP)

    P. Kassavetis, E. Shamim, K. Gottfried, M. Hallett (Salt Lake City, USA)

  • Eye-of-the-Tiger sign in Progressive Supranuclear Palsy

    R. Machado, I. Carvalho, D. Damas, J. Lemos, A. Morgadinho, F. Moreira (Coimbra, Portugal)

Jump to:  View All • a b c d [e] f g h i j k l m n o p q r s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
        • Help & Support
        • About Us
        • Cookies & Privacy
        • Wiley Job Network
        • Terms & Conditions
        • Advertisers & Agents
        Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
        Wiley